Managing infections in the immunocompromised patient.
Increasingly aggressive practices for treatment of patients with hematologic malignancies create challenges for successful management of infectious complications in immunocompromised patients. Infectious diseases practitioners face changing patterns of causative pathogens in their patients with febrile neutropenia, as well as evolving standards for empirical use of antimicrobial agents. The articles in this supplement issue of Clinical Infectious Diseases review these issues and their implications for current clinical practice.
Bodey
Gerald P
GP
Department of Infectious Diseases, M. D. Anderson Cancer Center, University of Texas, Houston, TX 77030, USA. gbodey@mdanderson.org
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D009369:Neoplasms / Q000276:immunology*; D009503:Neutropenia; D009894:Opportunistic Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents